Homepage
Author:
Deerfield Group
Posted Date:
March 18, 2026
GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes
Deerfield Group
March 18, 2026
Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting
Deerfield Group
March 17, 2026
Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
Deerfield Group
March 5, 2026
K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO
Deerfield Group
February 8, 2026
Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
Deerfield Group
February 4, 2026
The T1D Fund Strengthens Expertise With Appointment of Biotech Industry Veteran and Cell Therapy Expert Teresa Foy, Ph.D., to Advance Next Generation of Type 1 Diabetes (“T1D”) Therapies
Deerfield Group
January 23, 2026
Prev
1
2
